Advertisement

Vascular pharmacology of 5-hydroxytryptamine in humans

  • Gerald J. Blauw
  • Peter Van Brummelen
  • Pieter A. Van Zwieten
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

Forty yeas after its discovery the role of 5-hydroxytryptaine (5-HT) in the regulation of vascular tone in man still remains rather obscure. Soon after synthetic 5-HT became available it was shown that this monoamine influences vascular tone in a complex manner. Depending on the type of blood vessel and species investigate, as well as on the dose and route of administration, 5-HT was able to induce either vasodilatation or vasoconstriction [1, 2].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Page IH (1952): The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamine. J Pharmacol Exp Ther 105: 58–73.PubMedGoogle Scholar
  2. 2.
    Page IH, McCubbin JW (1956): Arterial Response to infused serotonin in normotensive dogs, cats, hypertensive dogs and man. Am J Physiol 184: 265–270.PubMedGoogle Scholar
  3. 3.
    Roddie IC, Shepherd JT, Whelan RF (1955): The action of 5-hydroxtryptamine on the blood vessels of the human hand and forearm. Brit J Pharmacol 10: 445–450.PubMedGoogle Scholar
  4. 4.
    Bock KD, Dengler H, Kuhn HM, Matthes K (1957): Die wirkung von 5-hydroxytryptamin auf blutdruk, haut- und muskeldurchblutung des menschen. Arch exper Path Pharmakol 230: 257–273.Google Scholar
  5. 5.
    Glover WE, Marshall RJ, Whelan RF (1957): The antagonsim of the vascular effects of 5-hydroxytryptamine by BOL 148 and sodium salicylate in the human subject. Brit J Pharmacol 12: 498–503.PubMedGoogle Scholar
  6. 6.
    Walsh JA (1967): Antagonism by methysergide of vascular effects of 5-hydroxytrypta- mine in man. Br J Pharmac Chemother 30: 518–530.CrossRefGoogle Scholar
  7. 7.
    Chang PC, Verlinde R, Bruning T, Van Brummelen P (1988): A microcomputer-based, R-wave triggered system for hemodynamic measurements in the forearm. Comput Biol Med 18: 157–163.PubMedCrossRefGoogle Scholar
  8. 8.
    Blauw GJ, Van Brummelen P, Chang PC, Vermeij P, Van Zwieten PA (1988): Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension 11: 256–263.PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson GM, Feibel FC, Cohen DJ (1987): Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and plasma ultrafiltrate. Life Sci 40: 1063– 1070.PubMedCrossRefGoogle Scholar
  10. 10.
    Blauw GJ, Van Brummelen P, Chang PC, Vermeij P, Van Zwieten PA (1988): The arterial and venous effects of serotonin in the forearm of healthy subjects is not age- related. J Cardivasc Pharmacol 36 (suppl. 1): 74–77.Google Scholar
  11. 11.
    Cohen ML, Berkowitz BA (1976): Vascular contraction: Effect of age and extracellular calcium. Blood Vessels 13: 139–154.PubMedGoogle Scholar
  12. 12.
    De Mey C, Vanhoutte PM (1981): Effect of age and spontaneous hypertension on the tachyphylaxis to 5-hydroxytryptamine and angiotensin II in the isolated rat kidney. Hypertension 3: 718–724.PubMedCrossRefGoogle Scholar
  13. 13.
    De La Lande IS, Cannel VA, Waterson JG (1966): The interaction of serotonin and noradrenaline on the perfused artery. Br J Pharmac Chemother 28: 255–272.CrossRefGoogle Scholar
  14. 14.
    Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982): Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 –468). Eur J Pharmacol 77: 281–287.PubMedCrossRefGoogle Scholar
  15. 15.
    Lüscher TF, Vanhoutte PM (1988): Are there interactions between S2-serotonergic and α1-adrenergic receptors in isolated canine arteries? J Cardiovasc Pharmacol 11 (suppl 1): S16–S21.CrossRefGoogle Scholar
  16. 16.
    Blauw GJ, Van Brummelen P, Chang PC, Vermeij P, Van Zwieten PA (1988): Direct and indirect vascular effects of serotonin in man [abstract]. Br J clin Pharmac 25: 629P–630P.Google Scholar
  17. 17.
    Scroop GC, Walsh JA (1968): Interactions between angiotensin, noradrenaline and serotonin on peripheral blood vessels in man. AustJ exp Biol med Sci 46: 573–580.CrossRefGoogle Scholar
  18. 18.
    Van Nueten JM, Leysen JE, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218: 217–230.PubMedGoogle Scholar
  19. 19.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Ridchardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 1986; 25: 563–576.CrossRefGoogle Scholar
  20. 20.
    Saxena PR, Verdouw PD (1982): Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol 332: 501–520.PubMedGoogle Scholar
  21. 21.
    Reneman RS, Bollinger A (1986): Vascular and microvascular effects of serotonin. Some conclusive remarks. Progappl Microcirc 10: 83–86.Google Scholar
  22. 22.
    Müller-Schweinitzer E (1984): Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphen- ectomy procedures for varicose veins. Naunyn-Schmiedeberg’s Arch Pharmacol 327: 299–303.CrossRefGoogle Scholar
  23. 23.
    Docherty JR, Hyland L (1986): An examination of 5-hydroxytryptamine receptors in human saphenous vein. Br J Pharmac 89: 77–81.CrossRefGoogle Scholar
  24. 24.
    Leysen JE, Gommeren W, Van Gompel P, Janssen PFM, Laduron PM (1985): Receptor binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611.PubMedGoogle Scholar
  25. 25.
    Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1982): Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats. J Pharmacol Exp Ther 222: 227–231.PubMedGoogle Scholar
  26. 26.
    Cocks TM, Angus JA (1983): Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305: 627–630.PubMedCrossRefGoogle Scholar
  27. 27.
    Peach MJ, Loeb AL, Singer HA, Saye J (1985): Endothelium-derived relaxing factor. Hypertension 1 (suppl 1): 194 – 1100.Google Scholar
  28. 28.
    Cohen RA, Vanhoutte PM (1985): Platelets, serotonin, and endothelial cells, p. 105–112 in: Vanhoutte PM (ed), Serotonin and the cardiovascular system. New York: Raven Press.Google Scholar
  29. 29.
    Furchott RF, Jothianandan D, Cherry PD (1984): Endothelium-dependent responses: The last three years. Biblthca cardiol 38: 1–15.Google Scholar
  30. 30.
    Lüscher TF, Vanhoutte PM (1988): Endothelium-dependent reponses in human blood vessels. Trends Pharmacol Sci 9: 181–184.PubMedCrossRefGoogle Scholar
  31. 31.
    Blauw GJ, Van Brummelen P, Van Zwieten PA (1988): Serotonin induced vasodilatation in the human forearm is antagonized by the selective 5-HT3 receptor antagonist ICS 205–930. Life Sci 43: 1441–1449.PubMedCrossRefGoogle Scholar
  32. 32.
    McGrath MA (1977): 5-Hydroxytryptamine and neurotransmitter release in canine blood vessels: inhibition by low and augmentation by concentrations. Circ Res 41:428–435.PubMedCrossRefGoogle Scholar
  33. 33.
    Engel G, Göthert M, Müller-Schweinitzer E, Schlicker E, Sistonen L, Stadler PA (1983): Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxyptamine autoreceptors in CNS and inhibitory 5-hydroxtrypta- mine receptors on sympathetic nerves. Naunyn-Schmiedeberg’s Arch Pharmacol 324: 116–142.CrossRefGoogle Scholar
  34. 34.
    Fozard JR (1984): Neuronal 5-HT receptors in the periphery. Neuropharmacol 23: 1473–1486.CrossRefGoogle Scholar
  35. 35.
    Saxena PR, Duncker DJ, Bom AH, Heiligers J, Verdouw PD (1986): Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: Evidence for the presence of “5-hydroxytryptamine1-like” receptors. Naunyn-Schmiede- berg’sArch Pharmacol 333: 198–204.CrossRefGoogle Scholar
  36. 36.
    Orwin JM, Fozard JR (1986): Blockade of the flare response to intradermal 5-hydroxy-tryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytrypta- mine receptors. Eur J Pharmacol 30: 209–212.CrossRefGoogle Scholar
  37. 37.
    Houston DS, Vanhoutte PM (1986): Serotonin and the vascular system. Role in health and disease, and implications for therapy. Drugs 31: 149–163.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • Gerald J. Blauw
  • Peter Van Brummelen
  • Pieter A. Van Zwieten

There are no affiliations available

Personalised recommendations